Phenibut: The Complete Supplement Guide

Quick Reference Card

Phenibut is not classified as a dietary supplement by the FDA. It is a synthetic psychoactive compound with documented dependence potential and severe withdrawal risk. This guide presents available evidence for informational purposes. Phenibut use carries significant risks that differ fundamentally from typical dietary supplements.

Overview

The Basics

Phenibut is a synthetic chemical closely related to GABA, one of your brain's main calming signals. Developed in Russia in the 1960s, it was originally designed to help military personnel and cosmonauts manage anxiety while maintaining mental clarity. In Russia and a few Eastern European countries, it is still prescribed by doctors for anxiety, insomnia, and certain neurological conditions.

Outside of Russia, phenibut occupies a murky legal space. It is not an approved medication in the United States, Europe, Canada, or Australia, yet for years it was sold online and in some retail stores labeled as a "dietary supplement" or "nootropic." The FDA has made clear that this labeling is illegal: phenibut does not qualify as a dietary ingredient under U.S. law. Despite this, it remains accessible through some online retailers.

People who use phenibut typically do so for its anti-anxiety effects, sleep improvement, or as a social confidence booster. At low doses, many users describe feeling calm, sociable, and mentally clear. However, phenibut carries substantial risks that set it apart from typical supplements. Tolerance develops rapidly, sometimes within days of daily use. Physical dependence can follow, and withdrawal can be severe and medically dangerous, including symptoms like seizures, hallucinations, and psychosis. These risks are well-documented in clinical case reports from emergency departments around the world.

This guide presents the available evidence on phenibut's pharmacology, effects, and risks so that readers can make informed decisions. It is not an endorsement of phenibut use.

The Science

Phenibut (beta-phenyl-gamma-aminobutyric acid; IUPAC: 4-amino-3-phenylbutanoic acid; CAS 1078-21-3) is a synthetic analog of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) that was first synthesized in Leningrad (now St. Petersburg) in the early 1960s [1]. It is structurally distinguished from endogenous GABA by the addition of a phenyl ring at the beta-position, which confers enhanced lipophilicity and enables passage across the blood-brain barrier, a property that GABA itself lacks [2].

Phenibut was included in the standard medical kit for Soviet cosmonauts aboard the Salyut space stations, reportedly as an anxiolytic that could reduce anxiety without impairing cognitive or psychomotor performance [1]. It remains a registered pharmaceutical in Russia, where it is prescribed under brand names including Anvifen, Fenibut, and Noofen for indications including anxiety disorders, insomnia, vestibular disorders, and alcohol withdrawal [4].

In Western countries, phenibut has no regulatory approval as a pharmaceutical. The U.S. FDA has determined that phenibut does not meet the statutory definition of a dietary ingredient under the Federal Food, Drug, and Cosmetic Act and has issued warning letters and court injunctions against companies marketing it as a supplement [8]. Australia classified phenibut as Schedule 9 (prohibited substance) effective February 2018 [9]. The WHO Expert Committee on Drug Dependence has maintained phenibut under surveillance since 2017, with a pre-review at the 44th ECDD meeting (2021) recommending continued monitoring rather than international scheduling [10].

The CDC documented a significant increase in phenibut exposures reported to U.S. poison centers from 2009 to 2019 [3], and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has classified it alongside new psychoactive substances.

Chemical & Nutritional Identity

Phenibut is structurally analogous to baclofen (beta-(4-chlorophenyl)-GABA), differing only in the halogen substitution on the phenyl ring. Despite this structural similarity, phenibut is approximately 30 times less potent than baclofen as a GABA-B receptor agonist [2].

Mechanism of Action

The Basics

Phenibut works by mimicking one of your brain's natural calming chemicals, GABA. Your nervous system uses GABA to slow things down, to calm overactive nerve signals, reduce anxiety, and prepare your body for sleep. Normally, GABA supplements taken by mouth cannot reach the brain because they are blocked by a protective barrier called the blood-brain barrier. Phenibut gets around this barrier thanks to an extra chemical structure (a phenyl ring) that makes it fat-soluble enough to pass through.

Once in the brain, phenibut activates GABA-B receptors, the same targets that prescription drugs like baclofen act on. This produces a calming, anxiety-reducing effect. It also appears to act on certain calcium channels in nerve cells (similar to how gabapentin and pregabalin work), which may contribute to its pain-reducing and anti-anxiety properties. At higher doses, it may also affect GABA-A receptors, the same receptors targeted by benzodiazepines like Xanax and Valium, which could explain the sedative and intoxicating effects reported at high doses.

The problem is that your brain adapts quickly to phenibut's presence. With regular use, the brain reduces its own GABA activity to compensate. When phenibut is then removed, the brain is left in a hyperexcitable state, which is what causes the severe withdrawal symptoms, including anxiety, insomnia, tremors, and in severe cases, seizures and hallucinations.

The Science

Phenibut exerts its primary pharmacological effects through three identified mechanisms [5][3][6]:

1. GABA-B Receptor Agonism (Primary Mechanism)
Phenibut acts as an agonist at GABA-B (metabotropic) receptors, the same target as baclofen. This inhibits presynaptic neurotransmitter release and produces anxiolytic and muscle-relaxant effects. Phenibut is approximately 30-fold less potent than baclofen at GABA-B receptors [1][2]. This ratio forms the clinical basis for baclofen substitution during phenibut withdrawal (10mg baclofen per 1g phenibut) [7].

2. Voltage-Dependent Calcium Channel Modulation (Gabapentinoid Activity)
Phenibut binds to the alpha2-delta subunit of voltage-dependent presynaptic calcium channels, a mechanism shared with gabapentin, pregabalin, and mirogabalin [3][10]. R-phenibut has been specifically identified as the more active enantiomer at this target. This gabapentinoid activity may contribute to phenibut's analgesic, anxiolytic, and anticonvulsant properties.

3. GABA-A Receptor Activity (Secondary, Dose-Dependent)
At higher concentrations, phenibut demonstrates activity at GABA-A (ionotropic) receptors, the primary target of benzodiazepines and barbiturates [4][10]. This may explain the dose-dependent sedation, intoxication, and potential for respiratory depression at supratherapeutic doses.

Additional activity: Phenibut has been reported to interact with beta-phenethylamine receptors, though this mechanism is less well-characterized [5].

Pharmacokinetics: Phenibut is rapidly absorbed and distributes to brain, kidneys, liver, and urine. Elimination half-life is approximately 5.3 hours [1][2]. It is not significantly metabolized and is excreted largely unchanged in urine.

Tolerance and Dependence Mechanism: Chronic GABA-B receptor agonism leads to receptor downregulation and compensatory glutamatergic upregulation. Upon cessation, the imbalance between reduced GABAergic inhibition and increased glutamatergic excitation produces a hyperexcitable withdrawal state with symptoms paralleling benzodiazepine and alcohol withdrawal [6][4].

Absorption & Bioavailability

The Basics

Phenibut is taken by mouth and is reported to absorb quickly due to its ability to cross the blood-brain barrier, something that regular GABA supplements cannot do effectively. The effects typically begin within 1 to 4 hours, though some users report onset as long as 6 hours after taking it, which has led to dangerous redosing when users mistakenly think the first dose did not work.

Taking phenibut on an empty stomach generally produces faster and more pronounced effects. Food slows absorption. The HCl (hydrochloride) form dissolves readily in water and is more commonly available, while the FAA (free amino acid) form is less acidic and may be gentler on the stomach.

There is limited formal pharmacokinetic data available from published Western studies. Most of what is known about absorption comes from Russian pharmaceutical literature, which is not readily accessible or evaluable in translation.

The Science

Formal pharmacokinetic data for phenibut in humans is limited. The enhanced lipophilicity conferred by the phenyl group enables passage across the blood-brain barrier, a critical distinction from endogenous GABA and supplemental GABA, which have negligible CNS penetration [1].

The elimination half-life is approximately 5.3 hours based on available data, with the compound distributing rapidly to brain, kidneys, liver, and urine [2]. Phenibut is reported to undergo minimal hepatic metabolism and is excreted primarily unchanged via renal clearance [1].

The two commercial salt forms may differ in absorption characteristics:

• Phenibut HCl -- Higher water solubility, faster dissolution, more acidic (may cause GI discomfort)
• Phenibut FAA (free amino acid) -- Lower water solubility, less acidic, reported by community users to be sublingual-compatible

Comprehensive pharmacokinetic studies (Cmax, Tmax, AUC, absolute bioavailability) in humans have not been published in Western peer-reviewed literature. The available pharmacokinetic parameters derive primarily from Russian pharmaceutical documentation and animal studies.

Research & Clinical Evidence

The Basics

Phenibut's evidence base is unusual among substances sold as supplements. While it has decades of clinical use in Russia, the Russian-language literature has not been systematically translated or subjected to the rigorous peer review standards expected in Western medicine. What we have from Western sources is primarily case reports, reviews, and poison center data, not the gold-standard randomized controlled trials that would typically support therapeutic claims.

The available evidence strongly supports that phenibut has real pharmacological effects: it genuinely reduces anxiety and promotes sleep. These are not placebo effects. However, the evidence equally strongly supports that it carries serious risks of dependence and withdrawal. The risk-benefit equation is very different from typical dietary supplements.

The Science

Anxiolytic Efficacy:
Clinical use in Russia since the 1960s for anxiety, insomnia, vestibular disorders, and alcohol withdrawal suggests therapeutic efficacy [1]. Russian clinical trial literature reportedly supports these indications, but as noted by the TGA (2017) and WHO ECDD (2021), "the associated clinical trial literature is unable to be evaluated critically at this time due to translation issues." No Western-conducted RCTs of phenibut for any therapeutic indication have been published.

Safety and Toxicity (Western Evidence):
The Western evidence base is dominated by case reports, case series, and systematic reviews focusing on toxicity and withdrawal:

• A systematic review of 15 phenibut withdrawal case reports (2010-2023) found average consumption of 13.6 g/day (SD=8g) among dependent individuals, with 87% male, average age 31.8 years [4].
• A comprehensive review of 29 withdrawal cases identified successful treatment with baclofen, benzodiazepines, and phenobarbital [6].
• The German GIZ-Nord poison center received 17 phenibut inquiries (2008-2022), with overdose range of 2-100g. No deaths or respiratory depression were observed, though 8 of 15 overdose cases were somnolent [3].
• U.S. poison center data showed increasing phenibut exposures from 2009 to 2019 [8].

Neuroprotective Effects (Preclinical):
R-phenibut demonstrated mitochondrial-protective effects in an experimental traumatic brain injury model. This is animal data only and does not support human therapeutic claims.

WHO Assessment (2021):
The 44th ECDD pre-review concluded phenibut has dose-dependent analgesic, antidepressant, and anxiolytic effects in animal models, with limited information on human abuse liability, withdrawal, and magnitude of misuse [10]. The committee recommended continued surveillance rather than international scheduling.

Evidence & Effectiveness Matrix

Evidence Strength scores are derived from the quality and volume of published research. Reported Effectiveness scores are from community sentiment analysis. Phenibut's unique status (not a dietary supplement, limited Western clinical trials) means Evidence Strength scores reflect safety/toxicity literature rather than efficacy trials.

Not scored (insufficient evidence or community data): Fat Loss, Muscle Growth, Weight Management, Appetite & Satiety, Food Noise, Energy Levels, Memory & Cognition, Emotional Aliveness, Emotional Regulation, Libido, Sexual Function, Joint Health, Inflammation, Pain Management, Recovery & Healing, Physical Performance, Gut Health, Digestive Comfort, Skin Health, Hair Health, Heart Health, Blood Pressure, Hormonal Symptoms, Temperature Regulation, Fluid Retention, Body Image, Immune Function, Bone Health, Longevity & Neuroprotection, Treatment Adherence, Daily Functioning.

Benefits & Potential Effects

The Basics

When used occasionally at low doses, phenibut users commonly report several benefits. The most consistent is anxiety reduction: many describe feeling calm, confident, and socially at ease without the mental fog that prescription anti-anxiety drugs can cause. Improved sleep quality is the second most reported benefit, with users describing deep, restorative sleep. Some also report improved mood, increased sociability, and better stress management on the days they take it.

However, these benefits come with an important asterisk. They are most reliably experienced with infrequent use (once per week or less). With more frequent use, tolerance builds rapidly, the benefits diminish, and the risks of dependence escalate. The acute benefits of phenibut cannot be separated from its significant risk profile.

The Science

Based on available sources, the following potential effects are supported by pharmacological mechanisms and community-level reporting:

Anxiolytic effects: GABA-B receptor agonism and alpha2-delta calcium channel modulation produce dose-dependent anxiolytic activity. Russian clinical use supports this indication [1]. Community reporting rates anxiety reduction as the primary benefit (8/10 Reported Effectiveness).

Sleep promotion: GABAergic activity promotes sleep onset and depth. Community reporting consistently cites sleep improvement (7/10 Reported Effectiveness). No dedicated sleep trials have been published.

Mood elevation: Users report improved mood and optimism, likely mediated through GABAergic disinhibition of reward circuitry. This is distinct from antidepressant action and may represent a hedonic/euphoric effect similar to other GABAergic substances.

Social disinhibition: Reduction of social anxiety and increased sociability are widely reported. Mechanism is consistent with anxiolytic activity. Community rating: 7/10 for Social Connection.

Neuroprotective potential (preclinical only): R-phenibut showed mitochondrial-protective effects in animal TBI models. This does not support human neuroprotective claims.

Knowing the possible side effects is the first step. Catching them early in your own experience is what keeps a supplement routine safe. Doserly lets you log any symptoms as they arise, tagging them with severity, timing relative to your dose, and whether they resolve on their own or persist.

The app's interaction checker cross-references everything in your stack, supplements and medications alike, flagging known interactions before they become a problem. It also monitors your total intake against established upper limits, alerting you if your combined sources of a nutrient are approaching thresholds where risk increases. Think of it as a safety net that works quietly in the background while you focus on the benefits.

Side Effects & Safety Considerations

The Basics

Phenibut's side effect profile is significantly more serious than typical dietary supplements. At any dose, common side effects include drowsiness, dizziness, nausea, and impaired balance. At higher doses, effects escalate to loss of consciousness, trouble breathing, and severe intoxication resembling alcohol blackouts.

The most dangerous aspect of phenibut is not what happens while you take it, but what happens when you stop. Dependence can develop in as little as 3 days of daily use. Withdrawal symptoms can include severe anxiety, insomnia, hallucinations, psychosis, seizures, and in rare cases, life-threatening complications requiring intensive care. These are not exaggerations. Emergency departments worldwide have published case reports of phenibut withdrawal requiring intubation, ICU admission, and weeks of medical management.

Phenibut does not appear on standard drug screens, which means if you go to an emergency room, doctors may not immediately identify what is causing your symptoms. Carrying information about phenibut use can be critical in a medical emergency.

The Science

Common Side Effects (Dose-Dependent):

• CNS depression: drowsiness, sedation, reduced consciousness [3]
• Dizziness, poor balance, vertigo
• Nausea and GI distress (particularly with HCl form)
• Fatigue

Serious Adverse Effects:

• Loss of consciousness and respiratory depression at high doses [3]
• Acute intoxication resembling benzodiazepine/alcohol intoxication [5]
• Myoclonus and dystonia [9][10]
• Hypothermia [10]
• One fatality with phenibut detected as a contributing factor [3]

Withdrawal Syndrome (Well-Documented):
Systematic review of 15 cases found [4]:

• Insomnia: 53% of cases
• Hallucinations: 53% of cases
• Muscle abnormalities (myoclonus, tremor, hypertonicity): 53%
• Anxiety: 40%
• Tachycardia: 20%
• Additional reported symptoms: psychosis, seizures, suicidal ideation, delirium, hypertension

The TGA documented withdrawal features including "tremors, anxiety, insomnia, hypertension, hyperhidrosis, psychosis, tachycardia, widening of QRS complex and convulsions" [9].

Drug Interactions:

• Sedative medications (CNS depressants): Additive CNS depression risk including respiratory depression
• Pregabalin/gabapentin: Shared mechanism of action. Combined use increases side effect risk
• Opioids: Combined use could increase risk of coma and respiratory depression [3]
• Alcohol: Potentiation of GABAergic effects. Case reports document severe outcomes with co-ingestion [2]

Pregnancy and Breastfeeding: Insufficient data. Avoid use.

Detection: Phenibut is not detected by standard urine or serum drug screens [4][6].

Dosing & Usage Protocols

The Basics

There is no FDA-approved dosing for phenibut because it is not an approved drug in Western countries. The dosing information below comes from Russian pharmaceutical guidelines and community experience reports. This is for informational purposes only and should not be interpreted as a recommendation to use phenibut.

In Russia, therapeutic doses range from 250mg to 750mg per day, typically divided into 2-3 doses. Some Russian protocols go up to 1,500mg per day for specific conditions. These are prescription-supervised doses, not self-medication recommendations.

Community users who report successful long-term use almost universally emphasize strict frequency limits: no more than once or twice per week, with many recommending every 10 days to prevent tolerance buildup. Even with this discipline, some users report that baseline anxiety and sleep worsen over months of regular use.

The gap between Russian therapeutic dosing and the doses seen in withdrawal case reports is striking: the average dose among people presenting with withdrawal was 13.6 grams per day, roughly 9 to 27 times the recommended Russian maximum.

The Science

Russian Therapeutic Dosing:

• Standard therapeutic range: 250-750mg/day in 2-3 divided doses [1]
• Maximum recommended: up to 1,500mg/day in clinical settings [4]
• Typical prescription duration: 2-6 weeks with tapering

Doses in Withdrawal Case Reports:

• Average: 13.6 g/day (SD=8g), range 1.5-28.5 g/day [4]
• Average duration before dependence: 8.2 months
• Dependence reported after as few as 3 days of daily use [4]
• Dependence reported at doses as low as 1g/day for 10 days [7]

Onset and Duration:

• Onset: typically 1-4 hours, but up to 6 hours in some individuals
• Duration of acute effects: 4-8 hours
• Elimination half-life: approximately 5.3 hours

Getting the dose right matters more than most people realize. Too little may be ineffective, too much wastes money or introduces risk, and inconsistency undermines both. Doserly tracks every dose you take, across every form, giving you a clear record of what you're actually consuming versus what you planned.

The app helps you compare RDA recommendations against therapeutic ranges discussed in the research, so you can see exactly where your intake falls. If you switch forms, say from a standard capsule to a liposomal liquid, Doserly adjusts your tracking to account for different bioavailabilities. Pair that with smart reminders that keep your timing consistent, and the precision that makes a real difference in outcomes becomes effortless.

What to Expect (Timeline)

First dose (Day 1):
Effects typically begin 1-4 hours after ingestion. At therapeutic doses (250-750mg), expect subtle anxiety reduction, mild relaxation, and potentially improved sociability. Higher doses (1-2g) produce more pronounced effects: significant anxiety reduction, euphoria, increased talkativeness, and drowsiness. Some users experience nausea, especially on an empty stomach with HCl form. Sleep on the first night is often reported as unusually deep and restorative.

Day 2 (The "afterglow"):
Many users report a positive afterglow the day following use, characterized by good mood, reduced anxiety, and restful feeling from deep sleep. Others report mild hangover-like symptoms: grogginess, headache, or continued drowsiness, particularly at higher doses.

Occasional use (weeks to months, 1x/week or less):
Users who maintain strict frequency limits report consistent anxiolytic and sleep benefits without significant tolerance. However, even at 1x/week, some users report that rebound anxiety on off-days gradually worsens over months. Baseline mood and anxiety may subtly deteriorate compared to pre-phenibut levels.

Frequent use (3+ days/week):
Tolerance develops rapidly. The same dose produces diminishing effects within 1-2 weeks. Users typically escalate dosage. Physical dependence can develop within 3-7 days of daily use. At this stage, continued use is increasingly motivated by avoidance of withdrawal symptoms rather than therapeutic benefit.

Cessation after dependence:
Withdrawal symptoms typically begin within 24-72 hours of last dose. Acute withdrawal (anxiety, insomnia, tremors, hallucinations) may last 3-14 days. Post-acute symptoms (anhedonia, anxiety, sleep disturbance) can persist for weeks to months. Medical supervision is strongly recommended for discontinuation after daily use.

Timelines in the research give you a general idea of when to expect results, but your body has its own schedule. Doserly tracks your progress against those benchmarks, letting you see whether your experience aligns with typical response curves or whether something in your protocol might need adjusting.

By logging biomarkers and subjective outcomes alongside your supplement intake, you build a personal timeline that shows exactly when changes started appearing and how they've progressed. The app's trend analysis highlights inflection points, weeks where things shifted for better or worse, so you have concrete data when deciding whether to continue, adjust your dose, or try a different form.

Interactions & Compatibility

Caution / Avoid

• Benzodiazepines (Xanax, Valium, Ativan, Klonopin) -- Additive GABA-A/B agonism. Significant risk of excessive sedation, respiratory depression, and loss of consciousness.
• Pregabalin (Lyrica) / Gabapentin -- Shared alpha2-delta calcium channel mechanism. Additive CNS depression. Twitching and myoclonus reported with combination.
• Opioids (codeine, oxycodone, morphine, fentanyl) -- Combined GABAergic and opioid CNS depression increases risk of respiratory failure, coma, and death [3].
• Alcohol -- Potentiation of GABAergic effects. Multiple case reports of severe adverse outcomes with co-ingestion. Risk of blackouts and dangerous impairment [2].
• Z-drugs (zolpidem, zaleplon) -- Additive sedation and CNS depression.
• Other sedating supplements (kava, valerian, high-dose melatonin) -- Additive CNS depression potential.
• GHB/GBL -- Overlapping GABAergic mechanism with extreme risk of respiratory depression.

Synergistic

• Caffeine -- Commonly combined by users to counteract phenibut-induced drowsiness while maintaining anxiolytic effect. Caffeine primarily antagonizes adenosine rather than GABA, so interaction is pharmacologically limited.
• L-theanine -- Mild GABAergic compound. Some users combine for synergistic relaxation. Additive sedation possible.

Condition Contraindications

• Substance use disorder history -- High risk of phenibut dependence development
• Concurrent benzodiazepine or opioid use -- Dangerous synergistic CNS depression
• Hepatic impairment -- Caution advised per community pharmacological discussion
• Renal impairment -- Phenibut is renally excreted; impairment may prolong effects
• Pregnancy / breastfeeding -- Insufficient safety data; avoid use

Cross-links will be expanded as more supplement guides are published.

How to Take / Administration Guide

The following is informational only. Phenibut is not a dietary supplement per FDA and its use carries documented risks of dependence and withdrawal.

Timing: Take on an empty stomach for faster absorption. Effects typically onset 1-4 hours after ingestion. Do not redose if effects have not appeared within 2 hours, as delayed onset up to 6 hours has been reported. Redosing is a common cause of accidental overdose.

With food or without: Empty stomach produces faster, stronger effects. Taking with food slows absorption and may reduce intensity. Some users prefer this as a way to moderate the effect.

Form considerations:

• Phenibut HCl -- Most common form. Water-soluble, mixes easily in liquid. Highly acidic; may cause throat irritation if not diluted properly, and stomach upset in sensitive individuals.
• Phenibut FAA (free amino acid) -- Less acidic, potentially easier on the stomach. Lower water solubility. Some users report it is suitable for sublingual administration.

Frequency (if used at all): The community consensus for risk minimization is no more than once per week, with many experienced users recommending every 10 days. Daily use, even at low doses, carries documented dependence risk within days to weeks.

What to avoid on phenibut days: Alcohol, benzodiazepines, opioids, and other CNS depressants. Driving or operating machinery if experiencing sedation.

Choosing a Quality Product

The FDA has determined that phenibut does not qualify as a dietary ingredient. Products marketed as dietary supplements containing phenibut are considered misbranded under federal law. The FDA has issued warning letters and obtained court injunctions against companies selling phenibut.

Because phenibut exists outside the regulated supplement and pharmaceutical markets in Western countries, standard quality assurance frameworks do not apply:

• No USP Verified products exist for phenibut
• No NSF International certification is available
• No ConsumerLab testing has been conducted (ConsumerLab reported on FDA warnings against phenibut in supplements)
• No Informed Sport or NSF Certified for Sport certification exists

A study by Cohen et al. (2021) measured the quantity of phenibut in dietary supplements before and after FDA warnings and found continued availability with variable actual content versus label claims [8].

If someone chooses to obtain phenibut despite these warnings:

• Powder purity is highly variable across online vendors
• Third-party certificates of analysis (COA) from vendors are the only available quality indicator, but their reliability is unverified
• HCl and FAA forms have different potencies by weight (HCl contains approximately 83% active phenibut by mass due to the salt)
• Accurate weighing with a milligram scale is essential due to the narrow therapeutic window
• Community reports frequently cite brand-specific quality differences, though these reports are subject to bias

Storage & Handling

• Temperature: Store at room temperature (15-25C / 59-77F)
• Light: Keep away from direct light; store in opaque or amber containers
• Moisture: Phenibut HCl is hygroscopic (absorbs moisture from air). Keep tightly sealed with desiccant packets if available. Clumping or crystallization indicates moisture exposure.
• Shelf life: Manufacturer-dependent; generally stable for 2+ years when properly stored
• Powder handling: Use a milligram-precision scale for accurate dosing. Do not estimate doses by volume (scoops) as density varies between batches and forms. This is a safety-critical consideration given the narrow margin between therapeutic and adverse-effect doses.
• Keep out of reach: Store securely away from children, adolescents, and anyone with substance use vulnerabilities. Phenibut powder is indistinguishable from many innocuous substances.

Lifestyle & Supporting Factors

For individuals who choose to use phenibut despite its risks, the following factors may help minimize harm:

Strict scheduling: Maintaining a written log of use dates helps prevent frequency creep. The most consistently cited harm-reduction strategy in community reports is rigid adherence to a maximum 1x/week schedule.

Baseline anxiety management: Addressing anxiety through evidence-based approaches (cognitive behavioral therapy, regular exercise, sleep hygiene, meditation) reduces the temptation to increase phenibut frequency. Phenibut should not substitute for comprehensive anxiety management.

Sleep hygiene: Since phenibut significantly affects sleep architecture, maintaining strong baseline sleep habits (consistent wake/sleep times, dark room, no screens before bed) helps prevent reliance on phenibut for sleep.

Exercise: Regular physical activity provides natural anxiolytic and mood-enhancing effects through endorphin and endocannabinoid release, reducing reliance on pharmacological anxiolytics.

Monitoring: Track mood, anxiety, and sleep quality on both phenibut and off-days. Deterioration of off-day baseline is an early warning sign of developing dependence.

No alcohol co-use: The combination carries documented risks and is consistently warned against across all sources.

Regulatory Status & Standards

United States:
Phenibut does not meet the statutory definition of a dietary ingredient under the FD&C Act. The FDA has issued warning letters to three companies (NeusoScience, Evol Nutrition Associates, Atomixx) in April 2019 and obtained a permanent injunction against "Chill6" in June 2023 for distributing products containing phenibut [8]. Products labeled as dietary supplements containing phenibut are misbranded under federal law. Phenibut is not a controlled substance under the Controlled Substances Act.

Australia:
Schedule 9 (prohibited substance) since February 1, 2018. This is the most restrictive scheduling category, meaning production, possession, sale, and use are prohibited except for approved research [9].

Germany:
Production, possession, use, trafficking, and administration are illegal [3].

Other European Countries:
Banned in Hungary, Italy, Lithuania, and the Netherlands.

Russia:
Prescription pharmaceutical. Available under brand names Anvifen, Fenibut, and Noofen for prescribed indications including anxiety, insomnia, and vestibular disorders [1][4].

International (WHO):
Under ECDD surveillance since 2017. Pre-reviewed at the 44th ECDD meeting (October 2021). The committee recommended continued surveillance rather than international scheduling due to limited data on abuse liability and magnitude of misuse [10]. Updated surveillance status confirmed March 2025.

Athlete-Specific:
Phenibut is not explicitly listed on the WADA 2025 Prohibited List by name. However, it falls under S0 (Non-Approved Substances): "Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use." Since phenibut is not approved by the FDA, EMA, or any Western regulatory authority, it would be captured under this blanket prohibition [11]. Phenibut is not detected by standard doping tests. No TUE pathway exists for phenibut in Western countries.

Athletes should avoid phenibut entirely. There is no certified-for-sport program (Informed Sport, NSF Certified for Sport, Cologne List) that tests for or certifies phenibut-containing products.

Frequently Asked Questions

Is phenibut legal in the United States?
Phenibut is not a controlled substance in the U.S., meaning possession is not criminalized. However, the FDA has determined that it cannot be legally sold as a dietary supplement. Products labeled as supplements containing phenibut are considered misbranded. It occupies a legal gray area: not illegal to possess, but illegal to market as a supplement.

How is phenibut different from taking GABA supplements?
Regular GABA supplements cannot effectively cross the blood-brain barrier, which means they have limited direct effects on brain function. Phenibut's added phenyl ring makes it fat-soluble enough to cross this barrier, giving it potent effects on brain GABA receptors. This is why phenibut has drug-like effects while GABA supplements generally do not.

Can phenibut be used safely?
Some community users report safe long-term use with strict protocols (once per week or less, low doses, no co-use with alcohol or sedatives). However, clinical literature documents dependence developing even at low doses with only 3-10 days of daily use. There is no established "safe use" protocol supported by clinical evidence. Individual risk factors, particularly a history of substance use disorders, significantly increase risk.

What should I do if I'm dependent on phenibut and want to stop?
Do not stop abruptly (cold turkey). Phenibut withdrawal can be medically dangerous. Consult a healthcare provider. The most common medical approach is either a gradual phenibut taper or substitution with baclofen (a structurally similar prescription medication) followed by a baclofen taper. Bring information about phenibut to your doctor, as many Western physicians are unfamiliar with it.

Does phenibut show up on drug tests?
No. Phenibut is not detected by standard urine or blood drug screens. There is no widely available commercial test for phenibut.

Is phenibut the same as baclofen?
They are structurally related (both are phenyl-substituted GABA analogs) and share the GABA-B receptor agonist mechanism. However, baclofen is approximately 30 times more potent and is an FDA-approved prescription medication. Baclofen is used medically to treat phenibut withdrawal due to its cross-tolerance with phenibut.

Myth vs. Fact

Myth: "Phenibut is just a natural supplement like GABA."
Fact: Phenibut is a synthetic pharmaceutical compound, not a natural substance. It does not occur in foods or living organisms. Unlike GABA supplements, it crosses the blood-brain barrier and has potent psychoactive effects. The FDA has ruled that it does not qualify as a dietary ingredient [8].

Myth: "You can't get addicted to phenibut if you keep doses low."
Fact: Clinical case reports have documented phenibut dependence developing at doses as low as 250mg three times daily (750mg total) used for several months, and even at 1g/day for just 10 days [7]. While lower doses reduce risk, frequency of use appears to be the primary driver of dependence, not dose alone.

Myth: "Phenibut withdrawal is like caffeine withdrawal, just uncomfortable."
Fact: Phenibut withdrawal can be medically dangerous. Documented withdrawal symptoms include seizures, hallucinations, psychosis, and symptoms severe enough to require ICU admission and intubation [9][6][4]. It more closely resembles benzodiazepine or alcohol withdrawal than caffeine withdrawal.

Myth: "Phenibut is safe because it's been used in Russia for decades."
Fact: Phenibut has been used as a prescription pharmaceutical in Russia under medical supervision with defined dosing protocols and duration limits. This is fundamentally different from unsupervised self-medication with unregulated products of variable purity purchased online. The TGA noted that Russian clinical trial literature "is unable to be evaluated critically" due to translation and methodological access issues [9].

Myth: "Phenibut is unregulated everywhere."
Fact: Phenibut is Schedule 9 (prohibited) in Australia, illegal in Germany, banned in Hungary, Italy, Lithuania, and the Netherlands, and under WHO surveillance globally [9][3][10]. The FDA has taken enforcement action against U.S. companies marketing it as a supplement [8].

Sources & References

Review Articles

[1] Lapin I. Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug. CNS Drug Rev. 2001;7(4):471-481.

[2] Ahuja T, Mgbako O, Katzman C, Grossman A. Phenibut (beta-Phenyl-gamma-aminobutyric Acid) Dependence and Management of Withdrawal: Emerging Nootropics of Abuse. Case Rep Psychiatry. 2018. PMCID: PMC5952553. https://ncbi.nlm.nih.gov/pmc/articles/PMC5952553/

[3] Bonnet U, Scherbaum N, Schaper A, Soyka M. Phenibutan -- an Illegal Food Supplement With Psychotropic Effects and Health Risks. Dtsch Arztebl Int. 2024. PMID: 38377332. https://pubmed.ncbi.nlm.nih.gov/38377332/

Systematic Reviews

[4] Stewart C, Simonsen H, Satyasi SK, Ashraf N, Sukpraprut-Braaten S. A Systematic Review of Phenibut Withdrawals. Cureus. 2024;16(9):e68775. PMCID: PMC11456982. https://pmc.ncbi.nlm.nih.gov/articles/PMC11456982/

Pharmacology & Toxicology

[5] Zhivilo et al. Phenibut: A drug with one too many 'buts'. Review. 2024. PMID: 39197876. https://pubmed.ncbi.nlm.nih.gov/39197876/

[6] Vetter et al. Phenibut: Review and Pharmacologic Approaches to Treating Withdrawal. Review. 2024. PMID: 38339875. https://pubmed.ncbi.nlm.nih.gov/38339875/

Case Reports

[7] DiFiore E, Pittman J. A Case of Phenibut Withdrawal Management and Detoxification Using Baclofen in the Outpatient Setting. Case Rep Psychiatry. 2024. PMID: 38993282. https://pubmed.ncbi.nlm.nih.gov/38993282/

Regulatory Sources

[8] U.S. FDA. Phenibut in Dietary Supplements. (2019/2023). https://www.fda.gov/food/information-select-dietary-supplement-ingredients-and-other-substances/phenibut-dietary-supplements

[9] TGA (Australia). Scheduling Delegate's Interim Decision: Phenibut. (2017). https://www.tga.gov.au/resources/publication/scheduling-decisions-interim/scheduling-delegates-interim-decisions-and-invitation-further-comment-accsacms-march-and-july-2017/23-phenibut

[10] WHO ECDD 44th Meeting. Pre-Review: Phenibut. Annex I. (2021). https://cdn.who.int/media/docs/default-source/controlled-substances/44ecdd_unsg_annex1.pdf

[11] WADA. 2025 Prohibited List. (2024). https://www.wada-ama.org/sites/default/files/2024-09/2025list_en_final_clean_12_september_2024.pdf

Related Supplement Guides

Same Mechanism (GABAergic)

• GABA — The parent neurotransmitter that phenibut mimics

Common Alternatives

• L-Theanine — Mild anxiolytic amino acid sometimes used as an alternative
• Magnesium — Natural GABA modulator with anxiolytic properties
• Ashwagandha — Adaptogenic herb with anxiolytic effects through different mechanisms

Related Pharmaceuticals

• Baclofen — Structurally related prescription GABA-B agonist used to treat phenibut withdrawal